Kevin Schuyler
Kevin Schuyler's purchase track record
How the stock did after each of Kevin Schuyler's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/19/2026 | VEEE | $10K | -61.6% | -40.8% | +15.6% |
| 9/29/2023 | ADIL | $2K | -33.1% | -55.8% | +22.3% |
| 12/21/2022 | VEEE | $2K | 0.0% | +15.6% | +12.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
USFM and Twin Vee Update Merger Deal Terms. USFM and Twin Vee have amended their merger agreement to adjust the ownership split to 93% and 7%. This revision changes the structure of the pending transaction between the two companies. The update provides clarity on how equity will be distributed following the merger.
Transaction History
| ADIL | ▲ Buy | Grant | 9,185 | $0 | 4/7/2026 | View on chart |
| VEEE | ▲ Buy | Open Market | 25,000 | $10K | 3/19/2026 | View on chart |
| VEEE | ▲ Buy | Grant | 61,166 | — | 11/26/2024 | View on chart |
| ADIL | ▲ Buy | Open Market | 700 | $2K | 9/29/2023 | View on chart |
| VEEE | ▲ Buy | Open Market | 600 | $1K | 12/22/2022 | View on chart |
| VEEE | ▲ Buy | Open Market | 763 | $1K | 12/21/2022 | View on chart |
| ADIL | ▼ Sell | Gift | 312,990 | $0 | 12/23/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Adial Pharmaceuticals Announces Nasdaq Inducement Grant
Adial Pharmaceuticals disclosed a new inducement grant in compliance with Nasdaq Listing Rule 5635(c)(4). This corporate action is relevant as it relates to the company's adherence to exchange listing requirements. The stock currently trades well below its 52-week high, with recent volume spikes observed alongside the announcement.
Adial Pharmaceuticals Announces Nasdaq Inducement Grant. Adial Pharmaceuticals disclosed a new inducement grant in compliance with Nasdaq Listing Rule 5635(c)(4). This corporate action is relevant as it relates to the company's adherence to exchange listing requirements. The stock currently trades well below its 52-week high, with recent volume spikes observed alongside the announcement.